Abivax S.A.

NASDAQ:ABVX

Biotechnology

Healthcare
$83.83 -0.61%

-$0.62 today

Market cap
$7.34B
Beta
-0.20
P/E (TTM)
-18.1
EPS (TTM)
-$4.83
52W Low $5.69High $148.83

Volume 1.19M

Average 1.59M

ABVX Income Tax Expense

Income taxes recognized for the period, including current and deferred tax.

Abivax S.A.NASDAQ: ABVX

Income Tax Expense · Q2 FY2026 · quarter ended Jun 2026

Income tax expense turns negative

Q2 FY2026 income tax expense was -€6.08M, compared with €0 a year earlier.

Context

  • Income tax expense increased in 1 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
-€6.08M— QoQ
Last fiscal yearDec 2025
€5.85M— YoY
Income Tax Expense past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Income Tax Expense history

EUR · from the income statement

Latest · FY2025
5.85M EUR
Year-over-year change
—

Income Tax Expense vs competitors

How ABVX compares with its peers on the latest reported figures

  • Peers report in different currencies, so income tax expense is compared through growth and share of revenue rather than absolute size.
ABVX Competitors
Income Tax Expense for ABVX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
NRIXNurix Therapeutics, Inc.LTM Aug 2026$13.34M USD+1636.3%—1.9%
ABVXAbivax S.A.FY2025€5.85M EUR———
AVTXAvalo Therapeutics, Inc.LTM Mar 2026$169K USD+47.0%+80.6%286.4%
ANABAnaptysBio, Inc.LTM Mar 2026$160K USD+240.4%+89.8%0.1%
IMMXImmix Biopharma, Inc.LTM Mar 2026$27.9K USD-33.6%+54.3%—
IVAInventiva S.A.FY2025€22K EUR-93.0%—0.5%
SYRESpyre Therapeutics, Inc.LTM Sep 2026$0 USD+100.0%—0.0%
RCUSArcus Biosciences, Inc.LTM Jun 2026$0 USD-100.0%—0.0%
SNDXSyndax Pharmaceuticals, Inc.LTM Mar 2026$0 USD——0.0%
ANNXAnnexon, Inc.LTM Mar 2026$0 USD———
ACRSAclaris Therapeutics, Inc.LTM Mar 2026$0 USD——0.0%
Peer median (excluding ABVX) —+47.0%+80.6%0.0%

Competitors are the stored peer set for ABVX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

EUR
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue45.52M50.76M000
Gross Profit(45.52M)(50.76M)000
Gross Margin—————
Research & Development47.78M48.3M103.18M146.53M177.76M
Selling, General & Admin5.58M7.49M28.82M38.9M72.87M
Operating Expenses(4.12M)14.07M127.38M172.98M246.06M
Depreciation & Amortization302K485K707K1.1M1.07M
EBITDA(38.59M)(53.32M)(133.21M)(162.71M)(300.7M)
EBITDA Margin—————
Operating Income(41.4M)(64.84M)(127.38M)(172.98M)(246.06M)
Operating Margin—————
Interest Income002.77M8.96M5.75M
Interest Expense3.56M6.94M13.83M12.43M28.48M
Other Income / Expenses(1.05M)4.1M(20.36M)(3.26M)(84.2M)
Income Before Tax(42.45M)(60.74M)(147.74M)(176.24M)(330.25M)
Pre-Tax Margin—————
Income Tax Expense00005.85M
Net Income(42.45M)(60.74M)(147.74M)(176.24M)(336.1M)
Net Margin—————
EPS (Basic)(2.75)(3.18)(3.43)(2.80)(4.65)
EPS (Diluted)(2.75)(3.18)(3.43)(2.80)(4.65)
Weighted Avg Shares15.46M19.09M43.07M63.05M69.53M
Weighted Avg Shares (Diluted)15.46M19.09M43.07M63.05M69.53M

Abivax S.A.

NASDAQ:ABVX

Intrinsic Alpha fair value

Locked

Current Price

$83.83

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.